Loading patent…
AssigneesMax-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Otto-Von-Guericke-Universitat Magdeburg, Helmholtz-Zentrum FüR Infektionsforschung GmbH
InventorsSascha KUPKE, Udo REICHL, Marc Dominique HEIN, Dunja BRUDER, ulfert RAND
Estimating the term…
In The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.
A method for prophylactic or therapeutic treatment of coronaviridae infection in an individual comprising administering the individual influenza virus interfering particles (DIPs).
-12. (canceled)
A method of therapeutically or prophylactically treating viral infection with coronaviridae in an individual in need thereof comprising administering the individual an effective amount of influenza virus interfering particles (DIPs).
Dependencies are inferred from the claim text.